Table 3.
Univariate and multivariate Cox regression analysis of patients.
| Characteristics | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | ||
| Age, years | >70/<70 | 1.006 | 0.532–1.901 | .98 | |||
| Gender | Female/male | 0.713 | 0.315–1.613 | .47 | |||
| BMI | >24/18.5–24/<18.5 | 1.32 | 0.699–2.491 | .93 | |||
| Diabetes | Yes/no | 1.246 | 0.521–2.98 | .62 | |||
| Visceral metastasis | Yes/no | 2.457 | 1.192–5.063 | .015 | 3.056 | 1.334–7.005 | .008 |
| Prior surgery | Yes/no | 2.597 | 1.186–5.685 | .017 | 2.599 | 0.484–9.945 | .26 |
| Prior chemotherapy | Yes/no | 2.301 | 1.009–5.247 | .048 | 1.17 | 0.206–6.646 | .85 |
| Combined targeted therapy | Yes/no | 2.058 | 0.932–4.544 | .074 | |||
| Combined radiotherapy | Yes/no | 1.085 | 0.526–2.238 | .82 | |||
| Type of PD-1 inhibitor | |||||||
| Camrelizumab | Reference | ||||||
| Tislelizumab | 0.551 | 0.238–1.279 | .16 | ||||
| Sintilimab | 0.723 | 0.336–1.558 | .40 | ||||
| Pembrolizumab | 1.527 | 0.489–4.711 | .46 | ||||
| CD3+ | High/low | 1.401 | 0.751–2.613 | .28 | |||
| CD3+CD4+ | High/low | 1.39 | 0.75–2.579 | .29 | |||
| CD3+CD8+ | High/low | 1.177 | 0.636–2.178 | .60 | |||
| CD16+CD56+ | High/low | 0.478 | 0.249–0.921 | .027 | 0.359 | 0.174–0.739 | .005 |
| CD19+ | High/low | 1.017 | 0.548–1.89 | .95 | |||
| CD4+/CD8+ ratio | High/low | 0.517 | 0.274–0.977 | .042 | 0.584 | 0.298–1.145 | .11 |
BMI = body mass index, CI = confidence interval, HR = hazard ratio.